---
document_datetime: 2023-09-21 21:53:51
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/eptifibatide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: eptifibatide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6638634
conversion_datetime: 2025-12-28 14:52:10.703861
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Eptifibatide Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0017              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                             | 21/04/2023                          |                                             | Annex II and PL                  |           |
| IA/0014              | B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits | 03/10/2022                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0013   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                              | 12/04/2022   | 16/12/2022   | SmPC                   |                                                                                                                                                                                                                                                            |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                          | 21/12/2021   | 16/12/2022   | Annex II and PL        |                                                                                                                                                                                                                                                            |
| IA/0011   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                  | 19/04/2021   | n/a          |                        |                                                                                                                                                                                                                                                            |
| R/0010    | Renewal of the marketing authorisation.                                                                                                                                                                                                | 23/07/2020   | 30/09/2020   | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Eptifibatide Accord in the approved indication remains favourable and recommended an unlimited validity for the Marketing Authorisation. |
| IB/0009   | B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products                                                                                                              | 06/11/2019   | n/a          |                        |                                                                                                                                                                                                                                                            |
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                       | 29/04/2019   | 21/02/2020   | Labelling              |                                                                                                                                                                                                                                                            |
| IAIN/0008 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 05/03/2019   | 21/02/2020   | Annex II and PL        |                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| IAIN/0007/G   | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch takes place   | 22/02/2019   | n/a        |                        | control/testing   |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------|
| T/0005        | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                | 18/01/2019   | 06/02/2019 | SmPC, Labelling and PL |                   |
| II/0004       | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                 | 12/07/2018   | n/a        |                        |                   |
|               | B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                 | 25/05/2018   | n/a        |                        | II/0003           |
|               | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                       | 24/03/2017   | n/a        |                        | IA/0002           |

<div style=\"page-break-after: always\"></div>

| IB/0001/G   | This was an application for a group of variations.   | 03/06/2016   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|